ResearchPUBMEDApr 13
This article helps doctors who read medical images understand rare tumors that grow in women's reproductive organs. These tumors are uncommon, affecting fewer than 6 out of every 100,000 people each year, which makes them hard to diagnose and treat. The article explains what these tumors look like on imaging scans and how doctors can better identify them to help plan treatment.
WHY IT MATTERSIf you have been diagnosed with an uncommon gynecological tumor, radiologists who understand these rare conditions are better equipped to provide accurate imaging reports that guide your treatment decisions.
ResearchBIORXIVApr 12
Scientists created animal models (using fish and mice) that mimic DeSanto-Shinawi Syndrome, a rare genetic disorder caused by mutations in the WAC gene. These animal models showed symptoms similar to what patients experience, including developmental delays, intellectual disability, autism-like behaviors, and seizures. This research helps scientists understand how WAC gene mutations cause these symptoms and could lead to better treatments in the future.
WHY IT MATTERSFor the first time, researchers have created animal models that reproduce the key symptoms of DeSanto-Shinawi Syndrome, which could accelerate the discovery of why patients develop autism, seizures, and developmental delays—and potentially identify new treatment targets.
ResearchPUBMEDApr 10
Doctors from around the world created a network called the International Neuroblastoma Risk Group to share information about neuroblastoma, a type of cancer that starts in nerve cells. They combined data from over 25,000 patients to help researchers understand the disease better and develop better treatment plans. This teamwork model shows how rare cancer research can be improved when hospitals and countries work together.
WHY IT MATTERSPatients with neuroblastoma now benefit from standardized treatment approaches and risk classifications developed through this international collaboration, which means more consistent and potentially better care regardless of where they receive treatment.
Clinical trialCLINICALTRIALSApr 6
Researchers are testing a new drug called zipalertinib to see if it helps people with early-stage lung cancer that has specific genetic mutations. Patients who had surgery to remove their tumors will receive either the new drug or a placebo (fake medicine) along with standard chemotherapy. The study wants to find out if zipalertinib can prevent the cancer from coming back better than chemotherapy alone.
WHY IT MATTERSIf you have early-stage NSCLC with uncommon EGFR mutations (like exon 20 insertions) and recently had surgery, this trial offers access to a targeted therapy specifically designed for your mutation type before it becomes widely available.
ResearchPUBMEDApr 5
Researchers looked at studies from 2014 to 2024 about the cost and value of special medicines for rare kidney diseases in poorer countries. They found that there isn't much research on whether these expensive medicines are worth the money in these areas. The study shows that doctors and governments need better information to decide if patients should have access to these treatments.
WHY IT MATTERSIf you have a rare kidney disease in a low- or middle-income country, this research highlights why your access to orphan drugs is limited — there's a major gap in evidence about whether these treatments are affordable and effective in your region.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called CYT107 to help people with HIV who have Kaposi Sarcoma (a type of cancer) and whose immune systems aren't responding well to treatment. CYT107 is designed to boost the immune system to help fight the cancer. This is a Phase 2 trial, meaning it's testing whether the drug works and is safe in a larger group of people. The trial is now accepting patients and will start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for people with HIV-related Kaposi Sarcoma who haven't responded to standard immune-boosting treatments, addressing a significant gap in care for this vulnerable population.
Clinical trialUNITERAREApr 5
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.
WHY IT MATTERSThis trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
Clinical trialUNITERAREApr 4
Researchers are testing a new drug called JL15003 to see if it can safely treat glioblastoma, a serious brain cancer that has come back after previous treatment. This is an early-stage study that will check both how safe the drug is and whether it helps patients live longer or feel better. The study is now accepting patients and will run starting in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with recurrent glioblastoma, a condition with very limited treatment choices after initial therapy fails.
🔴 BreakingDrug approvalOPENFDAApr 4
The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.
WHY IT MATTERSWithout information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.
ResearchUNITERAREApr 3
This is a research study looking for patients and families affected by rare diseases to share their thoughts and values about brain and nerve-related medical decisions. Researchers at St. Jude Children's Research Hospital want to understand what matters most to people living with rare diseases so they can make better ethical decisions in medical research and treatment. The study is now accepting participants and will start in April 2026.
WHY IT MATTERSThis study gives rare disease patients and caregivers a direct voice in shaping how medical ethics and brain-related research decisions are made — your input could influence future treatment guidelines and research practices.
Clinical trialUNITERAREApr 3
Researchers are testing a new treatment approach for elderly patients with a type of blood cancer (MDS or AML) that has come back or stopped responding to previous treatments. The study uses a combination of chemotherapy drugs followed by a stem cell transplant from a donor to try to help patients recover. This trial is now actively looking for patients to participate.
WHY IT MATTERSThis trial offers elderly patients with relapsed or refractory MDS/AML a potentially less toxic conditioning regimen before stem cell transplant — cladribine-bridged LABU may improve tolerability compared to standard high-dose approaches in this vulnerable population.
Clinical trialCLINICALTRIALSApr 3
Researchers are looking for 100 people with rare types of joint inflammation to better understand how these conditions develop and damage joints. Some of these inflammatory arthritides occur alongside rare autoimmune diseases like systemic sclerosis, while others develop as side effects from cancer immunotherapy drugs. By studying tissue samples and immune cells from patients, scientists hope to discover why these conditions happen and potentially develop better treatments.
WHY IT MATTERSIf you have rare inflammatory arthritis, systemic sclerosis with joint involvement, or developed joint inflammation after cancer immunotherapy, this trial could help researchers understand your condition better and may lead to more targeted treatments in the future.
Clinical trialCLINICALTRIALSApr 3
Doctors across Europe are building a database to track rare head and neck cancers like nasopharynx cancer and salivary gland cancer. They're recruiting 13,600 patients to help them understand how these cancers develop and improve treatment. This registry will help researchers learn more about these uncommon cancers so doctors can treat patients better in the future.
WHY IT MATTERSIf you have a rare head and neck cancer like nasopharynx or salivary gland cancer, joining this registry helps European specialists understand your condition better and could improve treatment options for patients like you.
Clinical trialUNITERAREApr 3
Researchers are testing a new technology called 'digital twins' to help prevent second strokes in patients with three rare brain conditions: moyamoya disease, cerebral amyloid angiopathy, and previous stroke history. A digital twin is a computer model of a patient's brain that doctors can use to predict what treatments might work best for that individual. This study will randomly assign patients to either receive care guided by this digital twin technology or standard care, and compare which approach prevents more strokes.
WHY IT MATTERSThis trial offers patients with moyamoya disease or cerebral amyloid angiopathy who have had a stroke access to personalized, AI-guided prevention strategies that could reduce their risk of future strokes.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a specific type of brain cancer called glioblastoma (GBM) to test a new drug combination. The study will test a drug called silevertinib combined with temozolomide in patients whose tumors have certain genetic features (unmethylated MGMT and EGFRvIII). This is an early-stage study to see if this combination works better than current treatments.
WHY IT MATTERSThis trial targets newly diagnosed GBM patients with unmethylated MGMT and EGFRvIII mutations—a subgroup with historically poor prognosis—and offers access to a potentially more effective treatment combination before it becomes widely available.
Clinical trialUNITERAREApr 3
Researchers at the University of Michigan are testing whether a powder made from grapes rich in anthocyanins (natural plant compounds) can help prevent atrial fibrillation—a heart rhythm problem—after heart surgery. This early-stage trial is now accepting patients. The study will test if this natural supplement is safe and if it works better than a placebo (fake treatment).
WHY IT MATTERSThis trial offers patients undergoing heart surgery a potential natural option to reduce their risk of developing irregular heartbeats after the operation, which affects up to 50% of post-operative cardiac patients.
Clinical trialUNITERAREApr 3
Researchers are testing a new combination of three drugs (RBS2418, tremelimumab, and durvalumab) to treat advanced hepatocellular carcinoma, a type of liver cancer that cannot be surgically removed. This is an early-stage clinical trial (Phase 2) that is currently accepting patients. The study aims to see if combining these drugs works better than existing treatments.
WHY IT MATTERSThis trial offers eligible patients with advanced unresectable hepatocellular carcinoma access to a novel three-drug combination that may provide a new treatment option beyond current standard therapies.
Clinical trialUNITERAREApr 3
Researchers are looking for African American cancer survivors to join a study about genetic testing. The study will test a new approach designed specifically for African American communities to help more people get tested for inherited cancer genes. Genetic testing can show if someone has genes that increase cancer risk, which helps with prevention and treatment planning.
WHY IT MATTERSThis trial addresses a critical gap: African American cancer survivors are significantly underrepresented in genetic testing programs, meaning many miss opportunities for personalized cancer prevention and family screening.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with gastroesophageal cancer (cancer of the food pipe and stomach) that has spread to the brain. This study will compare the genetic makeup of the original tumor with the cancer that spread to the brain to understand if they're the same or different. This information could help doctors choose better treatments for patients whose cancer has spread to the brain.
WHY IT MATTERSIf you have gastroesophageal cancer with brain metastases, this trial could help researchers understand why your cancer spread to the brain and potentially lead to more targeted treatment options in the future.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.